IQVIA艾昆纬：2025年巴基斯坦在丁型肝炎与脂肪性肝炎（MASH）临床试验中的优势白皮书（英文版）

Pakistan is rapidly emerging as a leading destination for Hepatitis D and Metabolic Associated Steatohepatitis (MASH) clinical trials, offering pharmaceutical and biotechnology companies access to large, treatment-naïve patient populations and a mature research ecosystem. With internationally aligned regulations, robust infrastructure, and proven operational excellence, Pakistan enables rapid recruitment, high patient retention, and reliable data delivery. Supported by IQVIA’s regional expert